Email
IZ Express #1,753: Pentavalent meningococcal recs, #ProtegeATuBaby resources during NIIW, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,753: Pentavalent meningococcal recs, #ProtegeATuBaby resources during NIIW, and more |
| Date | April 24, 2024 10:45 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,753: April 24, 2024
Top Stories
* "Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
* CDC reminds clinicians: nirsevimab (Beyfortus) season has ended in most jurisdictions; prepare to resume in October 2024
* Immunize.org updates its resource for healthcare professionals: “Don’t Be Guilty of These Preventable Errors in Vaccine Administration!”
* Use Immunize.org's revised temperature logs: now with more room to write min/max temperatures
* Immunize.org updates "Strategies to Improve Adult Vaccination Coverage"
* In time for NIIW: Vaccinate Your Family launches #ProtegeATuBaby, a bilingual initiative encouraging infant immunization
* “My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube.
* Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements welcomes one new facility
* Vaccines in the news
Immunize.org Website and Clinical Resources
* Spotlight on the website: Resources to enhance vaccine confidence and address concerns
Featured Resources
* Hip-hop themed videos highlight reasons to be vaccinated
* Before we run out! Place your order for these sturdy, laminated versions of the 2024 U.S. immunization schedules from Immunize.org.
Notable Publications
* "Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture" published in Journal of Adolescent Health
* "Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023" published in MMWR
* "COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024" published in MMWR
* "COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022" published in Emerging Infectious Diseases
Upcoming Events
* Virtual: NFID hosts webinar titled “Combating the Resurgence of Measles and Other Preventable Diseases” on April 30 at 11:00 a.m. (ET); CME credit offered
------------------------------------------------------------
[link removed]
------------------------------------------------------------
Top Stories
------------------------------------------------------------
"Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
CDC published Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023 ([link removed]) in the April 18 issue of MMWR.
ACIP recommends use of this product (MenABCWY, Penbraya, Pfizer) as an option when vaccination against all five vaccine-preventable meningococcal serogroups (A, B, C, W, and Y) is needed at the same visit and the Trumenba (Pfizer) brand of MenB vaccine is used for the MenB series. ACIP recommends this product may be administered to any person age 10 years or older, including off-label use in adults older than age 25 years. Doses of Penbraya should not be administered less than 6 months apart. A portion of the summary appears below.
The pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer Inc.]) protects against N. meningitidis serogroups A, B, C, W, and Y and is licensed for use among persons aged 10–25 years. . . .
On October 25, 2023, the Advisory Committee on Immunization Practices recommended that MenACWY-TT/MenB-FHbp may be administered to persons aged ≥10 years when both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit. . . .
MenACWY-TT/MenB-FHbp is the first pentavalent meningococcal vaccine approved for protection against serogroups A, B, C, W, and Y. Different manufacturers’ MenB vaccines are not interchangeable; when MenACWY-TT/MenB-FHbp is administered, subsequent doses of MenB should be from the same manufacturer (Pfizer Inc.). . . .
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* Immunize.org: Clinical Resources: Meningococcal ACWY ([link removed]) main page
* Immunize.org: Clinical Resources: Meningococcal B ([link removed]) main page
------------------------------------------------------------
CDC reminds clinicians: nirsevimab (Beyfortus) season has ended in most jurisdictions; prepare to resume in October 2024
The 2023 ACIP recommendation for administration of nirsevimab ([link removed]) (Beyfortus, Sanofi), the long-acting monoclonal antibody product for prevention of RSV disease in infants and toddlers, takes into account the seasonal nature of RSV infection. Nirsevimab use should begin October 1 and end March 31 in jurisdictions with RSV seasonality typical of the contiguous United States (the “lower 48”). Based on this, in most facilities, nirsevimab inventory should be stored properly for the coming months until its use resumes in October 2024.
Alaska and tropical climates may have RSV circulation patterns that differ from most of the contiguous United States. Locations with tropical climates include southern Florida, Hawaii, Guam, Puerto Rico, U.S. Virgin Islands, and U.S.-affiliated Pacific Islands. Providers in these jurisdictions should follow state, local, or territorial guidance on timing of nirsevimab administration.
Related Links
* CDC: Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 ([link removed]) (8/25/23)
* CDC: Frequently Asked Questions about RSV Immunization with Monoclonal Antibody for Children 19 Months and Younger ([link removed]) main page
* American Academy of Pediatrics: Nirsevimab Frequently Asked Questions ([link removed]) web page
* Immunize.org: Ask the Experts: Respiratory Syncytial Virus (RSV) ([link removed]) web page
------------------------------------------------------------
Immunize.org updates its resource for healthcare professionals: “Don’t Be Guilty of These Preventable Errors in Vaccine Administration!”
Immunize.org recently updated its resource for healthcare professionals: Don't Be Guilty of These Preventable Errors in Vaccine Administration! ([link removed]) We updated resources and broken web links and removed references to the Menactra (Sanofi) brand of MenACWY, which is no longer available.
Related Links
* Immunize.org: Ask the Experts: Administering Vaccines ([link removed]) web page
* Immunize.org: Clinic Tools: Administering Vaccines ([link removed]) main page
* Immunize.org: Handouts: Administering Vaccines ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 300 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Use Immunize.org's revised temperature logs: now with more room to write min/max temperatures
In March, Immunize.org updated its entire suite of materials ([link removed]) to align with CDC’s Vaccine Storage and Handling Toolkit ([link removed]). The materials now accommodate two options for monitoring temperatures in standard freezers or refrigerators:
* CDC-preferred continuous digital data loggers that display minimum and maximum temperatures (min/max) or
* Other acceptable temperature monitoring devices without min/max displays
In April, Immunize.org incorporated reader feedback to create more room on each of the four temperature logs ([link removed]) to document minimum and maximum temperatures on the chart:
* Temperature log for refrigerator – Celsius ([link removed])
* Temperature log for refrigerator – Fahrenheit ([link removed])
[link removed] [link removed]
* Temperature log for freezer – Celsius ([link removed])
* Temperature log for freezer – Fahrenheit ([link removed])
Related Links
* Immunize.org: Clinical Resources: Storage & Handling ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
* CDC: Vaccine Storage and Handling Resources ([link removed]) web section
* CDC: Vaccine Storage & Handling Toolkit ([link removed])
------------------------------------------------------------
Immunize.org updates "Strategies to Improve Adult Vaccination Coverage"
Immunize.org recently revised its 2-page resource titled Strategies to Improve Adult Vaccination Coverage ([link removed]). We removed references to the Menactra (Sanofi) brand of MenACWY, which is no longer available.
Related Links
* Immunize.org: Handouts: Adult Vaccination ([link removed]) main page
* Immunize.org: Handouts: Strategies and Policies for Healthcare Settings ([link removed]) main page
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
In time for NIIW: Vaccinate Your Family launches #ProtegeATuBaby, a bilingual initiative encouraging infant immunization
National Infant Immunization Week ([link removed]) (NIIW), April 22–29, highlights the importance of protecting infants from vaccine-preventable diseases. Since 1994, hundreds of communities have celebrated the crucial role vaccination plays in protecting our children, communities, and public health.
To observe NIIW, Vaccinate Your Family (VYF) now offers the Spanish-English #ProtegeATuBaby Sharing Toolkit ([link removed]) for downloadable social media graphics, key messages about vaccines recommended for babies, and sharable animated videos. Remember to use hashtag #ProtegeATuBaby when sharing on social media and tag @vaccinateyourfamily (@vaxyourfam on X) so VYF can amplify your posts.
CDC makes it simple to plan your NIIW activities by using their promotional materials ([link removed]) including English and Spanish logos, sample social media content, social graphics, and key messages. Please share your posts using the hashtag #ivax2protect.
Related Links
* CDC: National Infant Immunization Week ([link removed]) main page
* CDC: Promotional Materials ([link removed]) main page
* Vaccinate Your Family: #ProtegeATuBaby Sharing Toolkit ([link removed])
* Vaccinate Your Family: National Infant Immunization Week 2024 ([link removed]) main page
* Immunize.org: Parent Handouts ([link removed]) main page
------------------------------------------------------------
“My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now? ([link removed]) The video briefly describes routine pneumococcal vaccination of adults turning 65.
The 1-minute video is available on our YouTube channel ([link removed]), along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
------------------------------------------------------------
Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements welcomes one new facility
Immunize.org's Influenza Vaccination Honor Roll ([link removed]) recognizes facilities that take a stand for patient safety by implementing policies requiring healthcare personnel influenza vaccination. Immunize.org recently welcomed an additional healthcare organization.
* Silver Lake Hospital, Newark, NJ
Eligibility:
* Eligible organizations: hospitals, long-term care facilities, medical practices, pharmacies, professional organizations, health departments, and other government entities
* Requirements:
+ Your policy must require influenza vaccination for all staff
+ The application ([link removed]) must describe measures to prevent transmission of influenza from unvaccinated personnel to patients (e.g., masking for the entire work shift)
Related Links
* Immunize.org: Honor Roll Honorees: Influenza ([link removed])
* About the Influenza Vaccination Honor Roll ([link removed])
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Infectious Disease Special Edition: School Vaccine Mandates Key to Preventing Measles, Other Preventable Diseases ([link removed]) (4/15/24)
* Forbes: Life without Vaccines: Americans Who Never Forget ([link removed]) (4/16/24)
* Washington Post: Opinion: Measles Is More Contagious than the Coronavirus. And It’s Back. ([link removed]) (4/14/24)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the website: Resources to enhance vaccine confidence and address concerns
This week, we spotlight Immunize.org’s clinical resources for improving confidence in and addressing concerns about vaccinations. These provide medical professionals with practical resources that can be shared with patients and parents.
Located under the Clinical Resources menu, the Vaccine Confidence & Addressing Concerns section contains both an overview page and a list of topics.
The Overview Page lists topics such as safety, scheduling, religious concerns, and more than 100 personal accounts of people and families who have been affected by vaccine-preventable diseases. This page also provides links to educational materials from other trusted organizations.
One of these topics is “Improving the Vaccination Experience.” Anxiety about needles and injections is common among children and adults, so we developed resources to help providers reduce vaccine-related pain and anxiety. These are available as printable documents for both vaccine providers and recipients as well as video and webinar formats.
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Hip-hop themed videos highlight reasons to be vaccinated
As part of the CDC-funded National Network to Innovate for COVID-19 and Adult Vaccine Equity led by the Michigan State University School of Public Health, the Media Genesis team designed a public service announcement campaign ([link removed]) highlighting pioneering black scientists and encouraging residents of black communities to “listen to the science” and get the COVID-19 vaccine. The campaign was created in the form of hip-hop music videos. Local musicians from Detroit, Charlotte, and Baltimore contributed lyrics and recorded the vocals and the music was created by Third V Modern Entertainment.
Media Genesis Solutions also created Black Pioneers in Science ([link removed]) videos to increase awareness of scientific achievement in the African American community. One of these videos is on Dr. Kizzmekia Corbett, whose COVID-19-related work was central to the development of the Moderna mRNA vaccine and the Eli Lilly therapeutic monoclonal antibody.
View and share the Listen to the Science ([link removed]) and Black Pioneers in Science ([link removed]) videos.
------------------------------------------------------------
Before we run out! Place your order for these sturdy, laminated versions of the 2024 U.S. immunization schedules from Immunize.org.
Laminated versions of the 2024 U.S. child and adolescent immunization schedule ([link removed]) and the 2024 U.S. adult immunization schedule ([link removed]) are shipping. We anticipate selling out, so put in your order now!
While the schedules are available online from CDC at no cost, Immunize.org’s printed, laminated booklets are ideal for use in any busy healthcare setting where vaccinations are given.
* Durable: their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use
* Format: each schedule is produced in a 16-page, 8.5” X 11” booklet format; with color coding for easy reading, our laminated schedules replicate the original CDC formatting, including all tables and notes
* Easy access to CDC updates: CDC added an online addendum page to the schedule, where new recommendations from ACIP made during 2024 can be posted. The laminated schedule addendum pages include custom QR codes you can scan to view or print the current CDC addendum from CDC's website, as needed.
* Adult schedule bonus content: the adult schedule includes a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients
Pricing
1 copy: $10.00
2–4 copies: $9.50 each
5–19 copies: $8.50 each
20–99 copies: $7.50 each
100–499 copies: $6.00 each
500–999 copies: $5.00 each
1,000–1,999 copies: $4.00 each
2,000+ copies: $3.25 each
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page to view images of all the pages, to download the order form, and to order today!
For additional information, call 651-647-9009 or email [email protected].
Related Links
* Immunize.org: Laminated Child & Teen Immunization Schedules ([link removed]) (0–18 years) web page
* Immunize.org: Laminated Adult Immunization Schedules ([link removed]) (19 and older) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
"Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture" published in Journal of Adolescent Health
In the December 9 issue, Journal of Adolescent Health published Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture ([link removed](23)00586-4/fulltext#intraref009051). We have summarized a portion of the results section.
Chart validation in this study confirmed:
* Vaccine-associated syncope at a rate of 3.0 per 10,000 vaccination events
* Venipuncture-associated syncope at a rate of 16.3 per 10,000 venipuncture events
Incidence of vaccine-associated syncope increased with each additional simultaneously administered vaccine, from 1.5 per 10,000 vaccination events after a single vaccine to 9.9 per 10,000 vaccination events after three or more vaccines.
The study reports that syncope resulted in injury in about 15% of both vaccine and venipuncture events.
Immunize.org offers resources to vaccine recipients and healthcare providers that describe vaccination-associated fainting and simple measures to reduce the risk of fainting. Download Immunize.org's handouts, Vaccination-Related Syncope: Information for Healthcare Personnel ([link removed]) and Fainting Related to Vaccination: What You Need to Know ([link removed]) (also available in Spanish ([link removed])), to use in your practice.
Related Links
* Journal of Adolescent Health: Syncope and Vaccinations: A Needed Step Forward ([link removed](24)00037-5/fulltext#back-bib7) (April 2024)
* Immunize.org: Vaccination-Related Syncope: Information for Healthcare Personnel ([link removed]) (PDF)
* Immunize.org: Fainting Related to Vaccination: What You Need to Know ([link removed]) (PDF)
* Immunize.org: Fainting Related to Vaccination: What You Need to Know ([link removed]) (Spanish, PDF)
------------------------------------------------------------
"Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023" published in MMWR
CDC published Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023 ([link removed]) on April 18 in MMWR. A portion of the summary appears below.
During December 19, 2021–October 29, 2023, receipt of ≥2 doses of an original monovalent mRNA COVID-19 vaccine was 52% effective against pediatric COVID-19 hospitalization and 57% effective against critical illness related to COVID-19, when the last dose was received within the 4 months preceding hospitalization, but protection decreased over time. . . .
These findings support existing recommendations that children and adolescents aged 5–18 years remain up to date with COVID-19 vaccination given low vaccination coverage and waning effectiveness over time against COVID-19–related hospitalizations.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
"COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024" published in MMWR
CDC published COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024 ([link removed]) on April 18 in MMWR. A portion of the summary appears below.
Nursing home residents are at increased risk for severe COVID-19. . . .
Each week during October 16, 2023–February 11, 2024, 14.9%–26.1% of nursing homes reported one or more SARS-CoV-2 infections. Weekly rates of COVID-19–associated hospitalization ranged from 3.8 to 7.1 per 10,000 nursing home residents. By February 11, 2024, only 40.5% of residents had received an updated 2023–2024 COVID-19 vaccine. . . .
During the 2023–24 respiratory virus season, nursing home residents continued to have high rates of COVID-19–associated hospitalization, and up-to-date COVID-19 vaccination coverage remained low. Ongoing surveillance for SARS-CoV-2 infections and COVID-19–associated hospitalizations in this population is necessary to develop and evaluate evidence-based interventions for protecting nursing home residents.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* The Society for Post-Acute and Long-Term Care Medicine: Resources on immunization ([link removed])
------------------------------------------------------------
"COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022" published in Emerging Infectious Diseases
In the May 2024 issue, Emerging Infectious Diseases published COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022 ([link removed]). The abstract appears below.
During December 11, 2020–March 29, 2022, the US government delivered 700 million doses of COVID-19 vaccine to vaccination sites, resulting in vaccination of 75% of US adults during that period. We evaluated accessibility of vaccination sites. Sites were accessible by walking within 15 minutes by 46.6% of persons, 30 minutes by 74.8%, 45 minutes by 82.8%, and 60 minutes by 86.7%. When limited to populations in counties with high social vulnerability, accessibility by walking was 55.3%, 81.1%, 86.7%, and 89.4%, respectively. By driving, lowest accessibility was 96.5% at 15 minutes. For urban/rural categories, the 15-minute walking accessibility between noncore and large central metropolitan areas ranged from 27.2% to 65.1%; driving accessibility was 79.9% to 99.5%. By 30 minutes driving accessibility for all urban/rural categories was >95.9%. Walking time variations across jurisdictions and between urban/rural areas indicate that potential gains could have been made by improving walkability
or making transportation more readily available.
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: NFID hosts webinar titled “Combating the Resurgence of Measles and Other Preventable Diseases” on April 30 at 11:00 a.m. (ET); CME credit offered
NFID will host a webinar titled Combating the Resurgence of Measles and Other Preventable Diseases ([link removed]) , 11:00 a.m.–12:00 p.m. (ET) on April 30. NFID Medical Director Robert H. Hopkins, Jr., MD, will moderate the discussion featuring Yvonne A. Maldonado, MD, Stanford University; Sean T. O’Leary, MD, MPH, University of Colorado School of Medicine and Children’s Hospital Colorado; and Tami H. Skoff, MS, epidemiologist, CDC. This webinar will feature a panel discussion addressing vaccine recommendations and effective strategies to reduce the U.S. burden of measles, pertussis, and polio.
CME credit is available. There is no fee to participate in this activity, but preregistration is required.
Register for the webinar ([link removed]).
NFID hosts monthly webinars ([link removed]) to increase awareness of the importance of infectious disease prevention and treatment. CME, CNE, and CPE credits are available for select recordings. View all archived NFID webinars ([link removed]).
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,753: April 24, 2024
Top Stories
* "Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
* CDC reminds clinicians: nirsevimab (Beyfortus) season has ended in most jurisdictions; prepare to resume in October 2024
* Immunize.org updates its resource for healthcare professionals: “Don’t Be Guilty of These Preventable Errors in Vaccine Administration!”
* Use Immunize.org's revised temperature logs: now with more room to write min/max temperatures
* Immunize.org updates "Strategies to Improve Adult Vaccination Coverage"
* In time for NIIW: Vaccinate Your Family launches #ProtegeATuBaby, a bilingual initiative encouraging infant immunization
* “My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube.
* Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements welcomes one new facility
* Vaccines in the news
Immunize.org Website and Clinical Resources
* Spotlight on the website: Resources to enhance vaccine confidence and address concerns
Featured Resources
* Hip-hop themed videos highlight reasons to be vaccinated
* Before we run out! Place your order for these sturdy, laminated versions of the 2024 U.S. immunization schedules from Immunize.org.
Notable Publications
* "Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture" published in Journal of Adolescent Health
* "Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023" published in MMWR
* "COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024" published in MMWR
* "COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022" published in Emerging Infectious Diseases
Upcoming Events
* Virtual: NFID hosts webinar titled “Combating the Resurgence of Measles and Other Preventable Diseases” on April 30 at 11:00 a.m. (ET); CME credit offered
------------------------------------------------------------
[link removed]
------------------------------------------------------------
Top Stories
------------------------------------------------------------
"Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
CDC published Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023 ([link removed]) in the April 18 issue of MMWR.
ACIP recommends use of this product (MenABCWY, Penbraya, Pfizer) as an option when vaccination against all five vaccine-preventable meningococcal serogroups (A, B, C, W, and Y) is needed at the same visit and the Trumenba (Pfizer) brand of MenB vaccine is used for the MenB series. ACIP recommends this product may be administered to any person age 10 years or older, including off-label use in adults older than age 25 years. Doses of Penbraya should not be administered less than 6 months apart. A portion of the summary appears below.
The pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer Inc.]) protects against N. meningitidis serogroups A, B, C, W, and Y and is licensed for use among persons aged 10–25 years. . . .
On October 25, 2023, the Advisory Committee on Immunization Practices recommended that MenACWY-TT/MenB-FHbp may be administered to persons aged ≥10 years when both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit. . . .
MenACWY-TT/MenB-FHbp is the first pentavalent meningococcal vaccine approved for protection against serogroups A, B, C, W, and Y. Different manufacturers’ MenB vaccines are not interchangeable; when MenACWY-TT/MenB-FHbp is administered, subsequent doses of MenB should be from the same manufacturer (Pfizer Inc.). . . .
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* Immunize.org: Clinical Resources: Meningococcal ACWY ([link removed]) main page
* Immunize.org: Clinical Resources: Meningococcal B ([link removed]) main page
------------------------------------------------------------
CDC reminds clinicians: nirsevimab (Beyfortus) season has ended in most jurisdictions; prepare to resume in October 2024
The 2023 ACIP recommendation for administration of nirsevimab ([link removed]) (Beyfortus, Sanofi), the long-acting monoclonal antibody product for prevention of RSV disease in infants and toddlers, takes into account the seasonal nature of RSV infection. Nirsevimab use should begin October 1 and end March 31 in jurisdictions with RSV seasonality typical of the contiguous United States (the “lower 48”). Based on this, in most facilities, nirsevimab inventory should be stored properly for the coming months until its use resumes in October 2024.
Alaska and tropical climates may have RSV circulation patterns that differ from most of the contiguous United States. Locations with tropical climates include southern Florida, Hawaii, Guam, Puerto Rico, U.S. Virgin Islands, and U.S.-affiliated Pacific Islands. Providers in these jurisdictions should follow state, local, or territorial guidance on timing of nirsevimab administration.
Related Links
* CDC: Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 ([link removed]) (8/25/23)
* CDC: Frequently Asked Questions about RSV Immunization with Monoclonal Antibody for Children 19 Months and Younger ([link removed]) main page
* American Academy of Pediatrics: Nirsevimab Frequently Asked Questions ([link removed]) web page
* Immunize.org: Ask the Experts: Respiratory Syncytial Virus (RSV) ([link removed]) web page
------------------------------------------------------------
Immunize.org updates its resource for healthcare professionals: “Don’t Be Guilty of These Preventable Errors in Vaccine Administration!”
Immunize.org recently updated its resource for healthcare professionals: Don't Be Guilty of These Preventable Errors in Vaccine Administration! ([link removed]) We updated resources and broken web links and removed references to the Menactra (Sanofi) brand of MenACWY, which is no longer available.
Related Links
* Immunize.org: Ask the Experts: Administering Vaccines ([link removed]) web page
* Immunize.org: Clinic Tools: Administering Vaccines ([link removed]) main page
* Immunize.org: Handouts: Administering Vaccines ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 300 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Use Immunize.org's revised temperature logs: now with more room to write min/max temperatures
In March, Immunize.org updated its entire suite of materials ([link removed]) to align with CDC’s Vaccine Storage and Handling Toolkit ([link removed]). The materials now accommodate two options for monitoring temperatures in standard freezers or refrigerators:
* CDC-preferred continuous digital data loggers that display minimum and maximum temperatures (min/max) or
* Other acceptable temperature monitoring devices without min/max displays
In April, Immunize.org incorporated reader feedback to create more room on each of the four temperature logs ([link removed]) to document minimum and maximum temperatures on the chart:
* Temperature log for refrigerator – Celsius ([link removed])
* Temperature log for refrigerator – Fahrenheit ([link removed])
[link removed] [link removed]
* Temperature log for freezer – Celsius ([link removed])
* Temperature log for freezer – Fahrenheit ([link removed])
Related Links
* Immunize.org: Clinical Resources: Storage & Handling ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
* CDC: Vaccine Storage and Handling Resources ([link removed]) web section
* CDC: Vaccine Storage & Handling Toolkit ([link removed])
------------------------------------------------------------
Immunize.org updates "Strategies to Improve Adult Vaccination Coverage"
Immunize.org recently revised its 2-page resource titled Strategies to Improve Adult Vaccination Coverage ([link removed]). We removed references to the Menactra (Sanofi) brand of MenACWY, which is no longer available.
Related Links
* Immunize.org: Handouts: Adult Vaccination ([link removed]) main page
* Immunize.org: Handouts: Strategies and Policies for Healthcare Settings ([link removed]) main page
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
In time for NIIW: Vaccinate Your Family launches #ProtegeATuBaby, a bilingual initiative encouraging infant immunization
National Infant Immunization Week ([link removed]) (NIIW), April 22–29, highlights the importance of protecting infants from vaccine-preventable diseases. Since 1994, hundreds of communities have celebrated the crucial role vaccination plays in protecting our children, communities, and public health.
To observe NIIW, Vaccinate Your Family (VYF) now offers the Spanish-English #ProtegeATuBaby Sharing Toolkit ([link removed]) for downloadable social media graphics, key messages about vaccines recommended for babies, and sharable animated videos. Remember to use hashtag #ProtegeATuBaby when sharing on social media and tag @vaccinateyourfamily (@vaxyourfam on X) so VYF can amplify your posts.
CDC makes it simple to plan your NIIW activities by using their promotional materials ([link removed]) including English and Spanish logos, sample social media content, social graphics, and key messages. Please share your posts using the hashtag #ivax2protect.
Related Links
* CDC: National Infant Immunization Week ([link removed]) main page
* CDC: Promotional Materials ([link removed]) main page
* Vaccinate Your Family: #ProtegeATuBaby Sharing Toolkit ([link removed])
* Vaccinate Your Family: National Infant Immunization Week 2024 ([link removed]) main page
* Immunize.org: Parent Handouts ([link removed]) main page
------------------------------------------------------------
“My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now? ([link removed]) The video briefly describes routine pneumococcal vaccination of adults turning 65.
The 1-minute video is available on our YouTube channel ([link removed]), along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
------------------------------------------------------------
Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements welcomes one new facility
Immunize.org's Influenza Vaccination Honor Roll ([link removed]) recognizes facilities that take a stand for patient safety by implementing policies requiring healthcare personnel influenza vaccination. Immunize.org recently welcomed an additional healthcare organization.
* Silver Lake Hospital, Newark, NJ
Eligibility:
* Eligible organizations: hospitals, long-term care facilities, medical practices, pharmacies, professional organizations, health departments, and other government entities
* Requirements:
+ Your policy must require influenza vaccination for all staff
+ The application ([link removed]) must describe measures to prevent transmission of influenza from unvaccinated personnel to patients (e.g., masking for the entire work shift)
Related Links
* Immunize.org: Honor Roll Honorees: Influenza ([link removed])
* About the Influenza Vaccination Honor Roll ([link removed])
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Infectious Disease Special Edition: School Vaccine Mandates Key to Preventing Measles, Other Preventable Diseases ([link removed]) (4/15/24)
* Forbes: Life without Vaccines: Americans Who Never Forget ([link removed]) (4/16/24)
* Washington Post: Opinion: Measles Is More Contagious than the Coronavirus. And It’s Back. ([link removed]) (4/14/24)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the website: Resources to enhance vaccine confidence and address concerns
This week, we spotlight Immunize.org’s clinical resources for improving confidence in and addressing concerns about vaccinations. These provide medical professionals with practical resources that can be shared with patients and parents.
Located under the Clinical Resources menu, the Vaccine Confidence & Addressing Concerns section contains both an overview page and a list of topics.
The Overview Page lists topics such as safety, scheduling, religious concerns, and more than 100 personal accounts of people and families who have been affected by vaccine-preventable diseases. This page also provides links to educational materials from other trusted organizations.
One of these topics is “Improving the Vaccination Experience.” Anxiety about needles and injections is common among children and adults, so we developed resources to help providers reduce vaccine-related pain and anxiety. These are available as printable documents for both vaccine providers and recipients as well as video and webinar formats.
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Hip-hop themed videos highlight reasons to be vaccinated
As part of the CDC-funded National Network to Innovate for COVID-19 and Adult Vaccine Equity led by the Michigan State University School of Public Health, the Media Genesis team designed a public service announcement campaign ([link removed]) highlighting pioneering black scientists and encouraging residents of black communities to “listen to the science” and get the COVID-19 vaccine. The campaign was created in the form of hip-hop music videos. Local musicians from Detroit, Charlotte, and Baltimore contributed lyrics and recorded the vocals and the music was created by Third V Modern Entertainment.
Media Genesis Solutions also created Black Pioneers in Science ([link removed]) videos to increase awareness of scientific achievement in the African American community. One of these videos is on Dr. Kizzmekia Corbett, whose COVID-19-related work was central to the development of the Moderna mRNA vaccine and the Eli Lilly therapeutic monoclonal antibody.
View and share the Listen to the Science ([link removed]) and Black Pioneers in Science ([link removed]) videos.
------------------------------------------------------------
Before we run out! Place your order for these sturdy, laminated versions of the 2024 U.S. immunization schedules from Immunize.org.
Laminated versions of the 2024 U.S. child and adolescent immunization schedule ([link removed]) and the 2024 U.S. adult immunization schedule ([link removed]) are shipping. We anticipate selling out, so put in your order now!
While the schedules are available online from CDC at no cost, Immunize.org’s printed, laminated booklets are ideal for use in any busy healthcare setting where vaccinations are given.
* Durable: their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use
* Format: each schedule is produced in a 16-page, 8.5” X 11” booklet format; with color coding for easy reading, our laminated schedules replicate the original CDC formatting, including all tables and notes
* Easy access to CDC updates: CDC added an online addendum page to the schedule, where new recommendations from ACIP made during 2024 can be posted. The laminated schedule addendum pages include custom QR codes you can scan to view or print the current CDC addendum from CDC's website, as needed.
* Adult schedule bonus content: the adult schedule includes a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients
Pricing
1 copy: $10.00
2–4 copies: $9.50 each
5–19 copies: $8.50 each
20–99 copies: $7.50 each
100–499 copies: $6.00 each
500–999 copies: $5.00 each
1,000–1,999 copies: $4.00 each
2,000+ copies: $3.25 each
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page to view images of all the pages, to download the order form, and to order today!
For additional information, call 651-647-9009 or email [email protected].
Related Links
* Immunize.org: Laminated Child & Teen Immunization Schedules ([link removed]) (0–18 years) web page
* Immunize.org: Laminated Adult Immunization Schedules ([link removed]) (19 and older) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
"Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture" published in Journal of Adolescent Health
In the December 9 issue, Journal of Adolescent Health published Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture ([link removed](23)00586-4/fulltext#intraref009051). We have summarized a portion of the results section.
Chart validation in this study confirmed:
* Vaccine-associated syncope at a rate of 3.0 per 10,000 vaccination events
* Venipuncture-associated syncope at a rate of 16.3 per 10,000 venipuncture events
Incidence of vaccine-associated syncope increased with each additional simultaneously administered vaccine, from 1.5 per 10,000 vaccination events after a single vaccine to 9.9 per 10,000 vaccination events after three or more vaccines.
The study reports that syncope resulted in injury in about 15% of both vaccine and venipuncture events.
Immunize.org offers resources to vaccine recipients and healthcare providers that describe vaccination-associated fainting and simple measures to reduce the risk of fainting. Download Immunize.org's handouts, Vaccination-Related Syncope: Information for Healthcare Personnel ([link removed]) and Fainting Related to Vaccination: What You Need to Know ([link removed]) (also available in Spanish ([link removed])), to use in your practice.
Related Links
* Journal of Adolescent Health: Syncope and Vaccinations: A Needed Step Forward ([link removed](24)00037-5/fulltext#back-bib7) (April 2024)
* Immunize.org: Vaccination-Related Syncope: Information for Healthcare Personnel ([link removed]) (PDF)
* Immunize.org: Fainting Related to Vaccination: What You Need to Know ([link removed]) (PDF)
* Immunize.org: Fainting Related to Vaccination: What You Need to Know ([link removed]) (Spanish, PDF)
------------------------------------------------------------
"Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023" published in MMWR
CDC published Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023 ([link removed]) on April 18 in MMWR. A portion of the summary appears below.
During December 19, 2021–October 29, 2023, receipt of ≥2 doses of an original monovalent mRNA COVID-19 vaccine was 52% effective against pediatric COVID-19 hospitalization and 57% effective against critical illness related to COVID-19, when the last dose was received within the 4 months preceding hospitalization, but protection decreased over time. . . .
These findings support existing recommendations that children and adolescents aged 5–18 years remain up to date with COVID-19 vaccination given low vaccination coverage and waning effectiveness over time against COVID-19–related hospitalizations.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
"COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024" published in MMWR
CDC published COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024 ([link removed]) on April 18 in MMWR. A portion of the summary appears below.
Nursing home residents are at increased risk for severe COVID-19. . . .
Each week during October 16, 2023–February 11, 2024, 14.9%–26.1% of nursing homes reported one or more SARS-CoV-2 infections. Weekly rates of COVID-19–associated hospitalization ranged from 3.8 to 7.1 per 10,000 nursing home residents. By February 11, 2024, only 40.5% of residents had received an updated 2023–2024 COVID-19 vaccine. . . .
During the 2023–24 respiratory virus season, nursing home residents continued to have high rates of COVID-19–associated hospitalization, and up-to-date COVID-19 vaccination coverage remained low. Ongoing surveillance for SARS-CoV-2 infections and COVID-19–associated hospitalizations in this population is necessary to develop and evaluate evidence-based interventions for protecting nursing home residents.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* The Society for Post-Acute and Long-Term Care Medicine: Resources on immunization ([link removed])
------------------------------------------------------------
"COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022" published in Emerging Infectious Diseases
In the May 2024 issue, Emerging Infectious Diseases published COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022 ([link removed]). The abstract appears below.
During December 11, 2020–March 29, 2022, the US government delivered 700 million doses of COVID-19 vaccine to vaccination sites, resulting in vaccination of 75% of US adults during that period. We evaluated accessibility of vaccination sites. Sites were accessible by walking within 15 minutes by 46.6% of persons, 30 minutes by 74.8%, 45 minutes by 82.8%, and 60 minutes by 86.7%. When limited to populations in counties with high social vulnerability, accessibility by walking was 55.3%, 81.1%, 86.7%, and 89.4%, respectively. By driving, lowest accessibility was 96.5% at 15 minutes. For urban/rural categories, the 15-minute walking accessibility between noncore and large central metropolitan areas ranged from 27.2% to 65.1%; driving accessibility was 79.9% to 99.5%. By 30 minutes driving accessibility for all urban/rural categories was >95.9%. Walking time variations across jurisdictions and between urban/rural areas indicate that potential gains could have been made by improving walkability
or making transportation more readily available.
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: NFID hosts webinar titled “Combating the Resurgence of Measles and Other Preventable Diseases” on April 30 at 11:00 a.m. (ET); CME credit offered
NFID will host a webinar titled Combating the Resurgence of Measles and Other Preventable Diseases ([link removed]) , 11:00 a.m.–12:00 p.m. (ET) on April 30. NFID Medical Director Robert H. Hopkins, Jr., MD, will moderate the discussion featuring Yvonne A. Maldonado, MD, Stanford University; Sean T. O’Leary, MD, MPH, University of Colorado School of Medicine and Children’s Hospital Colorado; and Tami H. Skoff, MS, epidemiologist, CDC. This webinar will feature a panel discussion addressing vaccine recommendations and effective strategies to reduce the U.S. burden of measles, pertussis, and polio.
CME credit is available. There is no fee to participate in this activity, but preregistration is required.
Register for the webinar ([link removed]).
NFID hosts monthly webinars ([link removed]) to increase awareness of the importance of infectious disease prevention and treatment. CME, CNE, and CPE credits are available for select recordings. View all archived NFID webinars ([link removed]).
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp